RXL:ARCA-ProShares Ultra Health Care (USD)

ETF | Trading--Leveraged Equity | NYSE Arca

Last Closing

USD 102.28

Change

0.00 (0.00)%

Market Cap

USD 0.07B

Volume

1.70K

Analyst Target

N/A
Analyst Rating

N/A

ducovest Verdict

Verdict

About

The investment seeks daily investment results, before fees and expenses, that correspond to two times (2x) the daily performance of the Dow Jones U.S. Health CareSM Index. The fund invests in securities and derivatives that ProShare Advisors believes, in combination, should have similar daily return characteristics as two times (2x) the daily return of the index. The index measures the performance of the healthcare sector of the U.S. equity market. Component companies include, among others, health care providers, biotechnology companies, medical supplies, advanced medical devices and pharmaceuticals. The fund is non-diversified.

Inception Date: 30/01/2007

Primary Benchmark: DJ US Health Care TR USD

Primary Index: S&P 500 TR USD

Gross Expense Ratio: 1.06%

Management Expense Ratio: 0.95 %

Unadjusted Closing Price

Adjusted Closing Price

Assets

N/A

Top Holdings

N/A

Top Sectors

N/A

Top Regions

N/A

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-11-02 )

Largest Industry Peers for Trading--Leveraged Equity

Symbol Name Mer Price(Change) Market Cap
SOXL Direxion Daily Semiconductor B.. 1.10 %

N/A

USD 11.35B
QLD ProShares Ultra QQQ 0.95 %

N/A

USD 7.34B
FNGU MicroSectors FANG+ Index 3X Le.. 0.00 %

N/A

USD 5.84B
SSO ProShares Ultra S&P500 0.90 %

N/A

USD 5.40B
UPRO ProShares UltraPro S&P500 0.92 %

N/A

USD 4.05B
TECL Direxion Daily Technology Bull.. 1.17 %

N/A

USD 3.44B
YINN Direxion Daily FTSE China Bull.. 1.02 %

N/A

USD 2.18B
USD ProShares Ultra Semiconductors 0.95 %

N/A

USD 1.31B
LABU Direxion Daily S&P Biotech Bul.. 1.14 %

N/A

USD 0.91B
DPST Direxion Daily Regional Banks .. 1.02 %

N/A

USD 0.74B

ETFs Containing RXL

KGHG 4.13 % 0.00 %

N/A

N/A
ASWA:XETRA European Green Deal UCITS.. 2.35 % 0.00 %

N/A

USD 0.02B
VXM:CA First Asset Morningstar I.. 0.56 % 0.70 %

N/A

CAD 0.01B
IEUS iShares MSCI Europe Small.. 0.00 % 0.40 %

N/A

USD 0.10B
VXM-B:CA CI Morningstar Internatio.. 0.00 % 0.00 %

N/A

CAD 0.29B
SCZ iShares MSCI EAFE Small-C.. 0.00 % 0.39 %

N/A

USD 8.70B
LGWU:F Lyxor Index Fund - Lyxor .. 0.00 % 0.00 %

N/A

N/A
ZPRX:F SSgA SPDR ETFs Europe II .. 0.00 % 0.00 %

N/A

USD 0.24B
ZPRX:XETRA SPDR® MSCI Europe Small .. 0.00 % 0.00 %

N/A

USD 0.17B
1388:TSE 0.00 % 0.00 %

N/A

N/A

Market Performance

  Market Performance vs. Industry/Classification (Trading--Leveraged Equity) Market Performance vs. Exchange (NYSE Arca)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -86.01% 18% F 2% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -86.01% 18% F 2% F
Trailing 12 Months  
Capital Gain -84.09% 12% F 2% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -84.09% 12% F 2% F
Trailing 5 Years  
Capital Gain -76.28% 26% F 5% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -76.28% 26% F 6% D-
Average Annual (5 Year Horizon)  
Capital Gain 13.27% 31% F 74% C
Dividend Return 13.50% 30% F 70% C-
Total Return 0.22% 22% F 7% C-
Risk Return Profile  
Volatility (Standard Deviation) 30.23% 96% N/A 34% F
Risk Adjusted Return 44.64% 76% C+ 62% D
Market Capitalization 0.07B N/A N/A N/A N/A

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

What to not like:
Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Below median total returns

The company has under performed its peers on annual average total returns in the past 5 years.